CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
CERo Therapeutics (Nasdaq: CERO) presented encouraging preclinical results for its lead compound CER-1236 in ovarian cancer at the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting. The study demonstrated that CER-1236 effectively treated ovarian cancer cells without generating toxicity in animal models.
Key findings showed T cell engraftment in lymphoid organs following CER-1236 infusion, with no adverse clinical pathology or histopathological evaluations indicating toxicity. The research was presented in a poster titled 'TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity.'
The company plans to initiate Phase 1 trials in AML and expand testing to solid tumors in 2025, noting potential broader applications across cancer types, including Non-Small Cell Lung Cancers (NSCLC).
CERo Therapeutics (Nasdaq: CERO) ha presentato risultati preclinici incoraggianti per il suo composto principale CER-1236 nel trattamento del cancro ovarico durante il Meeting Scientifico Primaverile 2025 della SITC sulla Terapia Cellulare per Tumori Solidi. Lo studio ha dimostrato che CER-1236 tratta efficacemente le cellule del cancro ovarico senza generare tossicità nei modelli animali.
I risultati chiave hanno mostrato l'innesto delle cellule T negli organi linfatici dopo l'infusione di CER-1236, senza patologie cliniche avverse o valutazioni istopatologiche che indicassero tossicità. La ricerca è stata presentata in un poster intitolato 'L'espressione di TIM-4-L nei campioni di cancro ovarico può essere mirata da cellule T ingegnerizzate con recettori chimerici senza tossicità.'
L'azienda prevede di avviare studi di Fase 1 in AML ed espandere i test ai tumori solidi nel 2025, notando potenziali applicazioni più ampie tra i tipi di cancro, inclusi i Tumori Polmonari Non a Piccole Cellule (NSCLC).
CERo Therapeutics (Nasdaq: CERO) presentó resultados preclínicos alentadores para su compuesto principal CER-1236 en cáncer de ovario en la Reunión Científica de Terapia Celular para Tumores Sólidos de la SITC en Primavera de 2025. El estudio demostró que CER-1236 trató eficazmente las células de cáncer de ovario sin generar toxicidad en modelos animales.
Los hallazgos clave mostraron el injerto de células T en órganos linfoides tras la infusión de CER-1236, sin patologías clínicas adversas ni evaluaciones histopatológicas que indicaran toxicidad. La investigación fue presentada en un póster titulado 'La expresión de TIM-4-L en muestras de cáncer de ovario puede ser dirigida por células T quiméricas ingenierizadas sin toxicidad.'
La empresa planea iniciar ensayos de Fase 1 en AML y ampliar las pruebas a tumores sólidos en 2025, señalando aplicaciones potencialmente más amplias en tipos de cáncer, incluidos los Cánceres de Pulmón No Pequeñas Células (NSCLC).
CERo Therapeutics (Nasdaq: CERO)는 2025 SITC 봄 과학 세포 치료를 위한 고형 종양 회의에서 난소암에 대한 주요 화합물 CER-1236의 유망한 전임상 결과를 발표했습니다. 이 연구는 CER-1236이 동물 모델에서 독성을 생성하지 않고 난소암 세포를 효과적으로 치료했음을 보여주었습니다.
주요 발견은 CER-1236 주입 후 림프 기관에서 T 세포 이식이 이루어졌으며, 독성을 나타내는 임상 병리학적 또는 조직병리학적 평가가 없음을 보여주었습니다. 이 연구는 '난소암 샘플에서 TIM-4-L 발현이 독성 없이 엔지니어링된 키메라 섭취 수용체 T 세포에 의해 표적화될 수 있다'는 제목의 포스터로 발표되었습니다.
회사는 2025년 AML에서 1상 시험을 시작하고 고형 종양으로 테스트를 확장할 계획이며, 비소세포 폐암(NSCLC)을 포함한 여러 암 유형에 대한 잠재적인 광범위한 적용 가능성을 언급했습니다.
CERo Therapeutics (Nasdaq: CERO) a présenté des résultats précliniques encourageants pour son composé principal CER-1236 dans le cancer de l'ovaire lors de la Réunion Scientifique de Thérapie Cellulaire pour Tumours Solides de la SITC au printemps 2025. L'étude a démontré que CER-1236 traitait efficacement les cellules cancéreuses ovariennes sans générer de toxicité dans des modèles animaux.
Les résultats clés ont montré un engraftement des cellules T dans les organes lymphoïdes après l'infusion de CER-1236, sans pathologies cliniques adverses ou évaluations histopathologiques indiquant une toxicité. La recherche a été présentée dans un poster intitulé 'L'expression de TIM-4-L sur des échantillons de cancer de l'ovaire peut être ciblée par des cellules T à récepteur d'engulfement chimérique ingénierisées sans toxicité.'
L'entreprise prévoit de lancer des essais de phase 1 dans l'AML et d'élargir les tests aux tumeurs solides en 2025, notant des applications potentielles plus larges à travers les types de cancer, y compris les cancers du poumon non à petites cellules (NSCLC).
CERo Therapeutics (Nasdaq: CERO) präsentierte ermutigende präklinische Ergebnisse für seine Hauptverbindung CER-1236 bei Eierstockkrebs auf dem 2025 SITC Frühjahrswissenschaftlichen Treffen zur Zelltherapie für solide Tumoren. Die Studie zeigte, dass CER-1236 Eierstockkrebszellen effektiv behandelte, ohne in Tiermodellen Toxizität zu erzeugen.
Wichtige Ergebnisse zeigten die Einpflanzung von T-Zellen in lymphoide Organe nach der Infusion von CER-1236, ohne dass klinische Pathologien oder histopathologische Bewertungen auf Toxizität hinwiesen. Die Forschung wurde in einem Poster mit dem Titel 'TIM-4-L-Expression in Eierstockkrebsproben kann ohne Toxizität von ingenieerten chimärischen Aufnahmerezeptor-T-Zellen gezielt werden' präsentiert.
Das Unternehmen plant, 2025 mit Phase-1-Studien bei AML zu beginnen und die Tests auf solide Tumoren auszuweiten, wobei potenzielle breitere Anwendungen in verschiedenen Krebsarten, einschließlich nicht-kleinzelligem Lungenkrebs (NSCLC), angemerkt werden.
- Successful preclinical results showing efficacy in ovarian cancer treatment
- No toxicity observed in animal models
- Potential broad application across multiple cancer types (AML, NSCLC, ovarian)
- Advancing to Phase 1 clinical trials in 2025
- Still in preclinical stage, no human trial data available yet
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.
In the poster, titled, “TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” investigators demonstrated that CER-1236 treated ovarian cancer cells and did not generate toxicity in animal models (mice). Investigators found that following dosing, assessment of clinical and anatomic pathology after CER-1236 infusion showed T cell engraftment in lymphoid organs, but there were no in-life observations, clinical pathology, nor histopathological evaluations indicating toxicity caused by the compound. The poster is available today, March 13, 2025.
Chris Ehrlich, CERO CEO commented, “These data continue to build our wealth of studies that highlight CER-1236’s efficacy on cancer cells while maintaining a favorable safety profile. As we continue to progress toward the initiation of our Phase 1 trial in AML, these data demonstrate that our pursuit of solid tumor data also appears fruitful. Specifically, the data we have shown in both ovarian and Non-Small Cell Lung Cancers (NSCLC) is confirmation that CER-1236 may have broad utility across cancer types. We anticipate conducting trials in solid tumors in 2025 and are grateful for having had the opportunity to present these findings among such a distinguished audience.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo the timing and completion of the reverse stock split, and the acceptance and implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
FAQ
What were the key findings of CERo Therapeutics' (CERO) preclinical study for CER-1236 in ovarian cancer?
When will CERo Therapeutics (CERO) begin clinical trials for CER-1236?
Which cancer types is CERo Therapeutics' CER-1236 being developed to treat?
Where did CERo Therapeutics present their CER-1236 preclinical data in March 2025?
